Published in Clin Vaccine Immunol on November 21, 2007
Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog (2010) 2.30
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol (2009) 2.11
IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J Immunol (2010) 1.18
The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol (2010) 1.15
Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis (2010) 1.12
IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis (2009) 1.01
Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J Immunol (2011) 0.99
Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol (2011) 0.98
Immune responses to cholera in children. Expert Rev Anti Infect Ther (2012) 0.93
Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol (2013) 0.90
Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin Vaccine Immunol (2012) 0.88
Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot. Hum Vaccin Immunother (2014) 0.86
Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine. Clin Infect Dis (2015) 0.80
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers. Clin Exp Immunol (2015) 0.77
Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected Children. J Immunol (2015) 0.76
Concomitant administration of Mycobacterium bovis BCG with the meningococcal C conjugate vaccine to neonatal mice enhances antibody response and protective efficacy. Clin Vaccine Immunol (2011) 0.76
Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine. Clin Vaccine Immunol (2013) 0.75
No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine. J Allergy Clin Immunol (2016) 0.75
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis (2003) 5.73
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (2006) 5.56
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood (2004) 5.10
Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity (2001) 4.92
Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods (2004) 4.57
Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis (2005) 4.17
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 4.10
Lifetime of plasma cells in the bone marrow. Nature (1997) 3.99
Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis (2005) 3.72
Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med (2003) 3.64
Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol (1995) 3.32
Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis (2004) 3.31
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Maintenance of serum antibody levels. Annu Rev Immunol (2005) 3.20
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics (1998) 3.13
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol (1999) 2.73
Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis (2006) 2.54
Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun (2005) 2.32
Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol (1998) 2.12
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol (1998) 2.10
Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol (1989) 1.91
Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J (2004) 1.90
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (1999) 1.84
Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun (1998) 1.79
Stability of serotypes during nasopharyngeal carriage of Streptococcus pneumoniae. J Clin Microbiol (2003) 1.78
Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis (2003) 1.76
T-independent type II immune responses generate memory B cells. J Exp Med (2006) 1.76
The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine (1999) 1.73
Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol (2000) 1.59
Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol (2003) 1.49
Activation of human B lymphocytes after immunization with pneumococcal polysaccharides. J Clin Invest (1983) 1.43
Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine (2001) 1.42
Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun (1991) 1.42
Haemophilus influenzae type b conjugate vaccines. Immunology (2004) 1.37
Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol (2006) 1.35
Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med (2006) 1.32
Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol (2000) 1.28
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics (2000) 1.26
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. J Allergy Clin Immunol (1996) 1.19
Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun (1997) 1.19
Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J Infect Dis (2003) 1.14
The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology (2006) 1.14
Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine (2005) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol (2006) 1.12
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol (2004) 1.11
B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun (1999) 1.11
Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun (1999) 1.09
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr (1996) 1.08
Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine (1999) 1.07
Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens. Eur J Immunol (2003) 1.04
CD27 expression in the human splenic marginal zone: the infant marginal zone is populated by naive B cells. Tissue Antigens (2001) 1.03
Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol (2005) 1.02
Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis (1999) 1.00
Infant B cell responses to polysaccharide determinants. Vaccine (1998) 0.99
Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur J Immunol (2001) 0.99
Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines. Scand J Immunol (2005) 0.97
Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine. Emerg Infect Dis (2002) 0.97
IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells. Eur J Immunol (2001) 0.96
Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin Immunol Immunopathol (1993) 0.95
B cell mediated priming following pneumococcal colonization. Vaccine (2006) 0.95
Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine (2001) 0.95
Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect Immun (1997) 0.94
Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine (1993) 0.94
Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine (2005) 0.93
Vaccination-induced circulation of human B cells secreting type-specific antibodies against pneumococcal polysaccharides. Scand J Immunol (1987) 0.90
Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J (2000) 0.87
Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine (2000) 0.87
Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine (2004) 0.86
The relationship between immunization and circulating antigen-specific plaque-forming cells. Cell Immunol (1983) 0.85
Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers. Vaccine (2001) 0.85
Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol (2005) 0.83
Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood. Clin Vaccine Immunol (2007) 0.83
Antibody-mediated suppression of the immune response is determinant specific. Eur J Immunol (1985) 0.82
Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis (2005) 4.17
Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ (2006) 3.48
Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest (2006) 3.25
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol (2008) 3.04
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med (2010) 2.88
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA (2008) 2.88
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. Radiology (2006) 2.22
Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ (2010) 2.18
Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis (2006) 1.95
An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis (2014) 1.94
Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). Cochrane Database Syst Rev (2010) 1.92
Rapid turnover of effector-memory CD4(+) T cells in healthy humans. J Exp Med (2004) 1.85
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med (2004) 1.71
Ribosomal protein SA haploinsufficiency in humans with isolated congenital asplenia. Science (2013) 1.57
Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery (2006) 1.54
Adrenal cysts: natural history by long-term imaging follow-up. AJR Am J Roentgenol (2013) 1.53
Encephalitis in children. Arch Dis Child (2011) 1.53
B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood (2005) 1.52
The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines (2010) 1.50
Long-term immunological follow-up of children with haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis (2009) 1.42
Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis (2012) 1.42
High-throughput bacterial SNP typing identifies distinct clusters of Salmonella Typhi causing typhoid in Nepalese children. BMC Infect Dis (2010) 1.40
CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood (2006) 1.39
Haemophilus influenzae type b conjugate vaccines. Immunology (2004) 1.37
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology (2007) 1.35
Direct measurement of T cell subset kinetics in vivo in elderly men and women. J Immunol (2004) 1.34
Serum and mucosal antibody responses to pneumococcal protein antigens in children: relationships with carriage status. Eur J Immunol (2006) 1.34
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Altered CD45 expression and disease. Trends Immunol (2006) 1.32
Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis (2008) 1.26
Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis (2005) 1.25
Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naïve cattle. J Virol (2009) 1.24
Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J (2005) 1.24
Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood (2009) 1.23
Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) (2013) 1.22
Will telomere erosion lead to a loss of T-cell memory? Nat Rev Immunol (2004) 1.21
A fast and highly sensitive blood culture PCR method for clinical detection of Salmonella enterica serovar Typhi. Ann Clin Microbiol Antimicrob (2010) 1.20
Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis (2010) 1.20
Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One (2008) 1.16
Familial isolated congenital asplenia: case report and literature review. Eur J Pediatr (2009) 1.16
Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev (2011) 1.15
The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology (2006) 1.14
Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA (2005) 1.13
Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J (2007) 1.13
Meningococcal disease: clinical presentation and sequelae. Vaccine (2012) 1.13
Typhoid epidemiology, diagnostics and the human challenge model. Curr Opin Gastroenterol (2014) 1.12
Quadrivalent meningococcal conjugate vaccines. Vaccine (2009) 1.09
A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Negl Trop Dis (2008) 1.08
Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One (2009) 1.08
Cerebral infarct and meningitis secondary to Lemierre's syndrome. Pediatr Neurol (2004) 1.07
Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol (2009) 1.06
A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis (2011) 1.04
Management of severe malaria in children: proposed guidelines for the United Kingdom. BMJ (2005) 1.03
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine (2011) 1.02
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine (2006) 1.02
Hospital-based surveillance of invasive pneumococcal disease among young children in urban Nepal. Clin Infect Dis (2009) 1.02
Multifunctional nanoprobes for nanoscale chemical imaging and localized chemical delivery at surfaces and interfaces. Angew Chem Int Ed Engl (2011) 1.01
Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther (2005) 1.01
Nucleation control for large, single crystalline domains of monolayer hexagonal boron nitride via Si-doped Fe catalysts. Nano Lett (2015) 1.00
Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J (2011) 1.00
CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect Immun (2011) 1.00
Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA (2005) 0.99
Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology (2009) 0.99
Prolonged exposure of naïve CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology (2006) 0.99
Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine (2013) 0.98
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J (2013) 0.97
Beyond ultrasound: CT and MRI of ectopic pregnancy. AJR Am J Roentgenol (2014) 0.96
Cell-surface bound pertussis toxin induces polyclonal T cell responses with high levels of interferon-gamma in the absence of interleukin-12. Eur J Immunol (2003) 0.95
Measurement of proliferation and disappearance of rapid turnover cell populations in human studies using deuterium-labeled glucose. Nat Protoc (2009) 0.95
The burden of vaccine-preventable invasive bacterial infections and pneumonia in children admitted to hospital in urban Nepal. Int J Infect Dis (2010) 0.95
Is procalcitonin useful in early diagnosis of serious bacterial infections in children? Acta Paediatr (2005) 0.94
Prospects for prevention of Salmonella infection in children through vaccination. Curr Opin Infect Dis (2013) 0.93
The PPD-specific T-cell clonal response in UK and Malawian subjects following BCG vaccination: a new repertoire evolves over 12 months. Vaccine (2005) 0.93
Human microbial challenge: the ultimate animal model. Lancet Infect Dis (2012) 0.93
Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child (2013) 0.93
Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis (2006) 0.92
Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Genet (2004) 0.92
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J (2009) 0.92
A novel method of selective removal of human DNA improves PCR sensitivity for detection of Salmonella Typhi in blood samples. BMC Infect Dis (2012) 0.92
Combinations of CD45 isoforms are crucial for immune function and disease. J Immunol (2006) 0.92
Assent is not consent. J Med Ethics (2012) 0.91
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J (2014) 0.91
CD45 negatively regulates tumour necrosis factor and interleukin-6 production in dendritic cells. Immunology (2006) 0.91
Biliary cirrhosis in a child with inherited interleukin-12 deficiency. J Trop Pediatr (2008) 0.91
W135 in Africa: origins, problems and perspectives. Travel Med Infect Dis (2003) 0.90
A high-frequency polymorphism in exon 6 of the CD45 tyrosine phosphatase gene (PTPRC) resulting in altered isoform expression. Proc Natl Acad Sci U S A (2003) 0.90
Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest (2017) 0.90
Simultaneous immunization against tuberculosis. PLoS One (2011) 0.90
Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin-10 genes and susceptibility to invasive haemophilus influenzae serotype b infection in immunized children. Clin Infect Dis (2010) 0.89
H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis (2012) 0.89
Bloodstream infection among children presenting to a general hospital outpatient clinic in urban Nepal. PLoS One (2012) 0.88
Integration of apoptosis and telomere erosion in virus-specific CD8+ T cells from blood and tonsils during primary infection. Blood (2003) 0.88